Crunching the numbers. Responsibly.
Blood biomarkers are rapidly becoming established for Alzheimer's Disease (AD) diagnosis. However, there is a need for more scalable tools to reach the 99% of individuals with early cognitive impairment who are not seen in specialist healthcare services. A recent study validated a capillary blood sampling technique to detect the p-tau217 and GFAP biomarkers. Here we used our PROTECT research study to show that these biomarkers, when collected using self-administered fingerprick tests, correlate well with venous blood biomarkers and with cognition and function in 174 people who were cognitively normal or who had mild cognitive impairment or AD. They can be used in combination with computerised cognitive testing to identify people with the highest risk of AD. The GFAP biomarker appears to be associated with vascular risk, unlike p-tau217. Patient feedback indicates high acceptability and usability of the capillary test method, giving confidence in the feasibility of this technology. The work suggests that capillary blood biomarkers could be used to enable triage of people with varying levels of risk of AD in clinical practice and for clinical trials, and could be used outside of clinical settings.
these biomarkers, when collected using self-administered fingerprick tests, correlate well with venous blood biomarkers and with cognition and function in 174 people
strong venous correlations in 40 participants but modest, unadjusted cognitive associations in a compositionally heterogeneous cohort
They can be used in combination with computerised cognitive testing to identify people with the highest risk of AD.
cross-sectional threshold analyses lack pathology or longitudinal outcomes and contain unresolved subgroup inconsistencies
The GFAP biomarker appears to be associated with vascular risk, unlike p-tau217.
limited cross-sectional evidence from self-reported cardiovascular history does not test whether the biomarkers differ
Patient feedback indicates high acceptability and usability of the capillary test method, giving confidence in the feasibility of this technology.
feedback came from kit completers after 23% non-completion, and qualitative methods were not described
Capillary p-tau217 significantly correlated with episodic memory (r = 0.299, P < 0.001), attention (r = 0.197, P = 0.019) and executive function (r = 0.191, P = 0.021).
directly reported rank correlations support the stated associations, though they are modest and unadjusted
Derived from the full evaluation — not a separate score.
Strengths
Participants completed fingerprick collection without supervision and returned samples by post, directly examining an important practical step beyond clinic-based self-testing.
↳ Methods, Blood Biomarker Collection; Results, Figure 1
Capillary and venous p-tau217 and GFAP were strongly correlated in the 40-participant subgroup, providing an initial concurrent-validity signal for remotely collected samples.
↳ Results, Correlation Between Plasma and Capillary Blood Biomarkers
The Discussion distinguishes triage from diagnosis and identifies community assessment, primary-care monitoring, and clinical-trial pre-screening as intended pathways.
↳ Discussion, paragraphs 3–4 and final paragraph
Limitations
The reported p-tau217-positive and double-positive counts do not reconcile with the available sample and Table 4. Methods says ROC analyses defined the thresholds in this cohort, while Results calls them pre-specified, undermining the central triage analyses.
↳ Results, threshold analysis and Table 4; Methods, Statistical Analysis
Biomarker–cognition correlations pool healthy and dementia groups recruited through different pathways without adjustment for age, diagnosis, or recruitment source. Between-group composition may therefore contribute to the reported associations.
↳ Methods, Recruitment and Statistical Analysis; Results, Table 1
The cross-sectional study has no AD-pathology reference standard or longitudinal outcome, yet the Abstract says the approach can identify people with the highest AD risk. Dementia discrimination is modest, with AUCs of 0.656 and 0.688.
↳ Abstract; Results, Figure 2
The main contribution is the extension of capillary p-tau217 and GFAP measurement to unsupervised home collection with postal return, supported by a small venous comparison and user feedback. The quality score is constrained by pooled, unadjusted biomarker–cognition analyses, selection and missingness concerns, and reliance on self-reported functional and cardiovascular measures. More importantly, the threshold counts in Results and Table 4 do not reconcile, and Methods describes cohort-based threshold definition despite the Results calling the thresholds pre-specified. The paper therefore supports further evaluation of remote sampling but not current AD-risk triage or deployment.
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Limited2.9
Confidence mediumThe study meaningfully extends prior capillary validation to unsupervised home collection, postal return, cognitive measures, and acceptability assessment. The advance remains incremental because clinical risk stratification is not established by the cross-sectional data.
“self-administered capillary blood test completed at home and returned by post”
Spearman correlations, ROC analyses, a venous comparison, and age- and sex-adjusted cardiovascular models are reported, but the principal pooled biomarker–cognition analyses lack a confounding strategy. Attrition, unexplained p-tau217 missingness, self-reported measures, and internally inconsistent threshold subgroups add uncertainty.
“p-tau217 data were available for 143 participants”
The paper follows a readable sequence from sampling through correlations, threshold analyses, feasibility, and discussion. The Abstract nevertheless overstates modest cognitive correlations and presents cross-sectional triage analyses as identifying people with the highest AD risk.
“identify people with the highest risk of AD”
The paper positions the work against DROP-AD and identifies independent replication, longitudinal prediction, PET validation, and implementation as next steps. Those limitations are not fully carried into the stronger claims of established validity and triage utility.
“Further work is needed to replicate and expand this work”
Concerns4 of 4 checks
The counts and provenance of the biomarker thresholds are inconsistent across the cohort description, threshold Results, Table 4, and Statistical Analysis. These discrepancies affect the paper's central triage subgroup analyses rather than only peripheral reporting.
Ethics approvals and consent procedures are declared, and source-data provision is claimed. No competing-interests declaration appears in the supplied article text.
Flags: 2 declared / 5 total
17 references in manuscript 14 of 14 checkable references found in an index 3 have no canonical index record — counted, but not index-checkable 1 reference confirmed by manual review
No retraction notice found in Retraction Watch.
Sources: Retraction Watch ✓
Where this paper’s evidence sits on the path from initial observation to real-world use.
Unsupervised collection and postal return provide an in-situ feasibility signal, but the study does not prospectively validate a triage service against AD pathology or later outcomes. The paper itself calls for independent, longitudinal, PET, and implementation validation.
“determine the longitudinal predictive value of the capillary biomarkers”
AI-generated, human-governed. Something look off? Contact us to request a review.